SCHEMBL10024023

SCHEMBL10024023

C/C=C/[C@@H](O)C[C@@H](O)CC(C)=O

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8257920 0.83 SLC22A6 (0.48)
SCHEMBL7909130 0.83 SLC22A6 (0.48)
SCHEMBL14870401 0.73
SCHEMBL10024043 0.73 GAPDH (0.34)
SCHEMBL5868521 0.73 GAPDH (0.34)
SCHEMBL14026571 0.73 GAPDH (0.34)
SCHEMBL5868517 0.73 GAPDH (0.34)
SCHEMBL2337444 0.71 ALDH1A1 (0.56) ALDH1A1TDP1
SCHEMBL20530439 0.70 ALDH1A1 (0.57) ALDH1A1TDP1
SCHEMBL3512468 0.70 ALDH1A1 (0.50) ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476432-B2 Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof YUHAN CORPORATION (KR) 2013-07-02 US disclosed
US-20130096303-A1 PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF YUHAN CORPORATION (KR) 2013-04-18 US disclosed
US-8148550-B2 selected from fluvastatin, rosuvastatin, cerivastatin, glenvastatin or atorvastatin, by reduction or lactonization of chemical intermediate compounds, then hydrogenation, decyclization and deprotection of hydroxy groups RATIOPHARM GMBH (DE) 2012-04-03 US disclosed
US-7855302-B2 Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof CIBA SPECIALTY CHEMICALS CORP. (US) 2010-12-21 US disclosed
US-7692034-B2 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2010-04-06 US disclosed
US-7504532-B2 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-03-17 US disclosed
US-20080312466-A1 Synthesis and intermediates OHRLEIN REINHOLD 2008-12-18 US disclosed
US-20080249306-A1 Method for the Production of Statins RATIOPHARM GMBH (DE) 2008-10-09 US disclosed
US-7420078-B2 Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof CIBA SPECIALTY CHEMICALS CORP. (US) 2008-09-02 US disclosed
US-20080125601-A1 PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION BASF SE (DE) 2008-05-29 US disclosed
US-7317123-B2 Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) 2008-01-08 US disclosed
US-20070142662-A1 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives TEVA PHARMACEUTICAL INDUSTRIES LTD. 2007-06-21 US disclosed
US-20070093660-A1 Method for the production of statins RATIOPHARM GMBH (DE) 2007-04-26 US disclosed
US-7199261-B2 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) 2007-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312466-A1 Synthesis and intermediates HMGCR, SREBF1, COASY ALDH1A1 1326/4885TDP1 2328/4885
US-20080125601-A1 PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION HMGCR, DHCR7, CYP8B1 ALDH1A1 2063/4885TDP1 1623/4885
US-20070093660-A1 Method for the production of statins HMGCR, CYP11A1, CYP51A1 ALDH1A1 673/4885TDP1 3803/4885
US-20070142662-A1 Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives HMGCR, DHCR7, HCAR3 ALDH1A1 2430/4885TDP1 1538/4885
US-20130096303-A1 PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF HMGCR, COASY, PCSK9 ALDH1A1 2644/4885TDP1 4378/4885
US-20080249306-A1 Method for the Production of Statins HMGCR, COASY, PCSK9 ALDH1A1 862/4885TDP1 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.